Atara Biotherape Stock Price, News & Analysis

Atara Biotherapeutics (NASDAQ: ATRA) announced significant milestones for its T-cell immunotherapies in 2021, including FDA Fast Track designation for ATA188 in multiple sclerosis, enhancing its market position. The company aims for tab-cel^® to be the first allogeneic therapy approved in the EU for post-transplant lymphoproliferative disease, with decisions expected in 2022. Key presentations will occur at the J.P. Morgan Healthcare Conference on January 12. The company is also advancing CAR T programs targeting solid tumors. 2022 is projected to be a pivotal year for Atara's drug approvals.

Atara Biotherapeutics (NASDAQ: ATRA) announced the grant of 57,164 restricted stock units and options to purchase 64,925 shares of common stock to newly hired employees. These awards, approved by the Compensation Committee, are part of Atara’s 2018 Inducement Plan, intended as an incentive for new staff. The restricted stock units vest over four years, while stock options vest in a similar timeframe with a ten-year term. The exercise price for stock options is set at $16.89, equal to the stock's closing price on January 3, 2022.

Atara Biotherapeutics and Be The Match BioTherapies have extended their collaboration to supply healthy donor cells for Atara's off-the-shelf T-cell immunotherapy platform. This partnership aims to support patients with cancer and autoimmune diseases by utilizing Be The Match's extensive registry of over 22 million diverse HLA immune profiles. Atara's lead therapy, tab-cel, is currently under Phase 3 study and has recently submitted a marketing authorization application in the EU, marking a significant step towards availability for patients.

Atara Biotherapeutics (NASDAQ: ATRA) announced that its President and CEO, Pascal Touchon, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM PST / 5:15 PM EST. The presentation will highlight Atara's advancements in T-cell immunotherapy, focusing on their allogeneic Epstein-Barr virus (EBV) T-cell platform aimed at treating cancer and autoimmune diseases. A live audio webcast will be available on their website, with a replay accessible for 30 days.

Atara Biotherapeutics has announced promising results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for treating EBV+ PTLD, showing a 50% objective response rate. Among responders, 11 of 19 had a response lasting over six months, with a median time to response of 1.1 months. The one-year survival rate for responders was 89.2%, compared to 32.4% for non-responders. Tab-cel has been well-tolerated, with no new safety concerns, and is under review by the EMA for potential approval.

Atara Biotherapeutics announced promising results for ATA2271, a CAR T-cell therapy targeting mesothelioma, at the ESMO I-O Congress. Early data show that ATA2271 demonstrates good safety and significant persistence in patients after four weeks, with no severe adverse events reported. The therapy aims to improve outcomes in advanced mesothelioma, where median survival is only 9-17 months despite standard treatments. In vivo studies indicate that ATA2271 can eradicate tumors in mice, highlighting its potential in treating challenging solid tumors.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced the grant of 21,438 restricted stock units and stock options to newly hired employees, as part of the 2018 Inducement Plan, with the grants dated December 1, 2021. The restricted stock units vest over four years, while the stock options, priced at $17.36 each, also follow a four-year vesting period. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent critical for the company's mission in T-cell immunotherapy.

Atara Biotherapeutics has announced that the European Medicines Agency (EMA) has fully validated the Marketing Authorization Application (MAA) for its investigational treatment tabelecleucel (tab-cel). This therapy targets Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), a rare and aggressive cancer with no approved options. The MAA will be evaluated by the EMA’s Committee for Medicinal Products for Human Use (CHMP), with a decision expected in the second half of 2022. Tab-cel has shown a 50% objective response rate in clinical trials, demonstrating significant potential for this patient population.

Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced that CEO Pascal Touchon will participate in three virtual conferences. These include the Cowen 5th Annual IO Next Summit on November 15, 2021, at 9:45 a.m. EST, the Stifel 2021 Virtual Healthcare Conference, also on November 15, 2021, at 4:40 p.m. EST, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 10:05 a.m. EST. Live webcasts will be available on their website, with archived replays accessible for 30 days.